Repligen Corporation is a medical instruments & supplies business based in the US. Repligen Corporation shares (RGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $127.85 – a decrease of 9.65% over the previous week. Repligen Corporation employs 1,778 staff and has a trailing 12-month revenue of around $650.4 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $127.85 |
|---|---|
| 52-week range | $102.97 - $182.52 |
| 50-day moving average | $140.96 |
| 200-day moving average | $146.06 |
| Wall St. target price | $183.13 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.41 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $126.88 from 2025-05-07
| 1 week (2025-05-01) | -7.52% |
|---|---|
| 1 month (2025-04-09) | 2.45% |
| 3 months (2025-02-07) | -18.69% |
| 6 months (2024-11-08) | -9.82% |
| 1 year (2024-05-09) | -23.05% |
|---|---|
| 2 years (2023-05-08) | -18.97% |
| 3 years (2022-05-06) | 156.97 |
| 5 years (2020-05-08) | 3.28% |
Valuing Repligen Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Repligen Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Repligen Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Repligen Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Repligen Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $113.4 million.
The EBITDA is a measure of a Repligen Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $650.4 million |
|---|---|
| Operating margin TTM | 5.59% |
| Gross profit TTM | $332.7 million |
| Return on assets TTM | 0.92% |
| Return on equity TTM | -1.16% |
| Profit margin | -3.53% |
| Book value | $35.34 |
| Market Capitalization | $7.7 billion |
TTM: trailing 12 months
We're not expecting Repligen Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Repligen Corporation's shares have ranged in value from as little as $102.965 up to $182.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repligen Corporation's is 1.269. This would suggest that Repligen Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.